Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)

A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01574430

Enrollment

131

Registered

2012-04-10

Start date

2010-12-31

Completion date

2014-12-31

Last updated

2016-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Brief summary

The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.

Interventions

PROCEDUREPDT

30% or 50% verteporfin dose PDT was given to patients with CSC

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* patients with CSC * patients signed the ICF * patients with course of CSC less than 6 months * patients did not undertake any treatment for CSC

Exclusion criteria

* patients with porphyria * patients allergic to verteporfin * pregnant or nursing women * poor patients compliance * sever liver dysfunction * dioptric media opacities which make it difficult to exam fundus

Design outcomes

Primary

Measure	Time frame
Change from baseline in BCVA	1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

Secondary

Measure	Time frame
Leakage at RPE level in FA	1 week
Change from baseline in central retinal thickness	1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year
The incidence rate of adverse event	1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026